Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only
"Japan Cancer Drug Market, Dosage, Price and Clinical Trials Insight 2025" Report Highlights:
Japan Cancer Drug Market Opportunity: > US$ 15 Billion by 2025
Insight on Cancer Drugs In Clinical Trials: 360 Drugs
Ongoing Clinical Trials for Cancer Drugs: 1600 Trials
Marketed Cancer Drug Clinical Insight by Companies and Indication: 141 Drugs
Cancer Drug Price, Dosage and Sales Insight: 250 Graphs
Cancer Clinical Pipeline By Company, Indication and Phase
Cancer drug market in Japan is witnessing positive growth outlook similar to patterns observed at global levels. The domestic and multinational companies operating in Japan have launched several innovative products in the market driving the overall sales levels in recent years. The increasing geriatric population, RandD spending for new drug innovation, availability of targeted drug therapies are the prominent factors leading to above average growth of cancer drugs market in Japan. The future market growth for cancer drugs and therapies is expected to be almost 70% in absolute terms by 2025 as compare to 2018 levels.
Targeted therapy has the leading share in the Japan cancer drug market while the immunotherapy is the second leading type of therapy. This is due to the ability of targeted therapies to kill only malignant cells thereby exhibiting better treatment outcomes. In addition, elevated efficacy and higher survival rates associated with the use of targeted therapy drugs are other reasons that fuel the growth of the market. In the case of immunotherapy, it is the fastest growing segment in Japan pharmaceutical market as it is widely accepted as an ideal treatment option as these drugs are potentially harmless to the other living cells of the body, which makes them less toxic as compared to other modes of cancer therapies. Hormonal therapy and chemotherapy are not commonly used in Japan as chemotherapy has several adverse effects and hormonal therapy is not able to treat all type of cancers.
In Japan, prostate and lung cancer therapeutics will lead the cancer drug market in upcoming years, which is mainly due to presence of huge geriatric population of Japan. Currently, about 28% of the total population of Japan belongs to the age more than 65 years and this share is expected to increase in upcoming years. Further, the breast cancer drug market will also emerge as the leading segment of Japan caner drug market in near future as the cases of breast cancer is increasing rapidly in Japan. The overall Cancer cases in Japan are also rising and hence the demand of anticancer drugs is expected to increase rapidly in future years.
Japanese government will play a prominent role in the rapid growth of cancer drug market by providing favorable policies framework for easy drug approval, production and marketing of products. A policy framework change is required in order to make drug approval process simpler so that the globally available products of leading MNCs can enter the Japanese market and are easily accessible to desired targeted population. In addition to this, it is also necessary to make the drug approval process faster so that the essential and highly effective drugs get approve on right time. As the leading regional companies of Japan is witnessing sales breakdown, the government of Japan can play a major role to encourage these companies for continuous production of the branded as well as generic anticancer drugs.
Several new drugs targeting different type of cancer are about to get approved by PMDA very soon, which will take this market segment to the next level. About 1617 cancer related clinical trials related to more than 350 cancer drugs are under investigation in Japan in which about 30% trials are in late development stage. The investments related to research and development is also increasing and many innovative cancer targeting therapies is expected to get approved in Japan, which will act as game changer in the treatment of cancer.
The future of Japanese cancer drug market seems to the sustain the past growth trends and will continue to its upward growth trajectory in coming years. Cancer drug market opportunity is expected to surpass US$ 15 Billion by 2025 driven by increasing number of clinical trials, availability of multiple products and the favorable steps undertaken by various stake holders of the pharmaceutical market. The Japan cancer drug market growth will take place at tremendous pace and this segment will emerge as an ocean of opportunities in near future.